PARP inhibition in ovarian cancer: what is still missing?

被引：0
|
作者：
Morotti, Matteo [1 ,2 ]
Ghisoni, Eleonora [1 ,3 ]
机构：
[1] Ludwig Inst Canc Res, Batiment AGORA, CH-1005 Lausanne, Switzerland
[2] CHUV Ctr Hosp Univ Vaudois, Dept Gynecol, CH-1011 Lausanne, Switzerland
[3] CHUV Ctr Hosp Univ Vaudois, Dept Oncol, Immunooncol Serv, CH-1011 Lausanne, Switzerland
来源：
EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY | 2022年 / 43卷 / 01期
关键词：
EXPRESSION;
D O I：
10.31083/j.ejgo4301016
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：143 / 145
页数：3
相关论文
共 50 条
  • [1] PARP inhibition in ovarian cancer
    Saul, Helen
    [J]. EUROPEAN JOURNAL OF CANCER, 2010, 46 (12) : 2136 - 2136
  • [2] PARP Inhibition in Recurrent Ovarian Cancer
    Moore, Kathleen N.
    Pothuri, Bhavana
    Monk, Bradley
    Coleman, Robert L.
    [J]. CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2020, 18 (10) : 647 - 655
  • [3] PARP inhibition and synthetic lethality in ovarian cancer
    Eskander, Ramez N.
    Tewari, Krishnansu S.
    [J]. EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2014, 7 (05) : 613 - 622
  • [4] Rucaparib in the landscape of PARP inhibition in ovarian cancer
    Colomba, Emeline
    Pautier, Patricia
    Pommeret, Fanny
    Leary, Alexandra
    [J]. EXPERT REVIEW OF ANTICANCER THERAPY, 2019, 19 (06) : 437 - 446
  • [5] PARP Inhibition as Frontline Therapy in Ovarian Cancer
    Moore, Kathleen N.
    Pothuri, Bhavana
    Monk, Bradley
    Coleman, Robert L.
    [J]. CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2020, 18 (09) : 550 - 556
  • [6] PARP Inhibition in Ovarian Cancer: State of the Science
    Gunderson, Camille C.
    Moore, Kathleen N.
    [J]. GYNECOLOGIC ONCOLOGY, 2015, 136 (01) : 8 - 10
  • [7] Maintenance Therapy With PARP Inhibition in Ovarian Cancer
    Herzog, Thomas J.
    [J]. CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2022, 20 (09) : 539 - 541
  • [8] Combined PARP and Immune Checkpoint Inhibition in Ovarian Cancer
    Lee, Elizabeth K.
    Konstantinopoulos, Panagiotis A.
    [J]. TRENDS IN CANCER, 2019, 5 (09): : 524 - 528
  • [9] PARP inhibition: A promising therapeutic target in ovarian cancer
    Musella, A.
    Marchetti, C.
    Gasparri, M. L.
    Salerno, L.
    Casorelli, A.
    Domenici, L.
    Imperiale, L.
    Ruscito, I.
    Halim, T. Abdul
    Palaia, I.
    Di Donato, V.
    Pecorini, F.
    Monti, M.
    Muzii, L.
    Panici, P. B.
    [J]. CELLULAR AND MOLECULAR BIOLOGY, 2015, 61 (06) : 44 - 61
  • [10] What Is the Place of PARP Inhibitors in Ovarian Cancer Treatment?
    Joyce F. Liu
    Ursula A. Matulonis
    [J]. Current Oncology Reports, 2016, 18
12345